- Home
- PHK vs DNA Comparison
PHK vs DNA Comparison
Compare PHK & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHK
- DNA
- Stock Information
- Founded
- PHK 2003
- DNA 2008
- Country
- PHK United States
- DNA United States
- Employees
- PHK N/A
- DNA N/A
- Industry
- PHK Finance/Investors Services
- DNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PHK Finance
- DNA Health Care
- Exchange
- PHK Nasdaq
- DNA Nasdaq
- Market Cap
- PHK 842.0M
- DNA 895.1M
- IPO Year
- PHK N/A
- DNA N/A
- Fundamental
- Price
- PHK $4.86
- DNA $13.39
- Analyst Decision
- PHK
- DNA Strong Sell
- Analyst Count
- PHK 0
- DNA 1
- Target Price
- PHK N/A
- DNA $9.00
- AVG Volume (30 Days)
- PHK 491.5K
- DNA 1.8M
- Earning Date
- PHK 01-01-0001
- DNA 11-11-2025
- Dividend Yield
- PHK 12.61%
- DNA N/A
- EPS Growth
- PHK N/A
- DNA N/A
- EPS
- PHK N/A
- DNA N/A
- Revenue
- PHK N/A
- DNA $230,815,000.00
- Revenue This Year
- PHK N/A
- DNA N/A
- Revenue Next Year
- PHK N/A
- DNA $14.41
- P/E Ratio
- PHK N/A
- DNA N/A
- Revenue Growth
- PHK N/A
- DNA 25.21
- 52 Week Low
- PHK $4.13
- DNA $5.00
- 52 Week High
- PHK $5.15
- DNA $17.58
- Technical
- Relative Strength Index (RSI)
- PHK 34.04
- DNA 48.64
- Support Level
- PHK $4.86
- DNA $12.44
- Resistance Level
- PHK $4.99
- DNA $16.50
- Average True Range (ATR)
- PHK 0.04
- DNA 1.60
- MACD
- PHK -0.02
- DNA -0.09
- Stochastic Oscillator
- PHK 38.35
- DNA 18.39
About PHK Pimco High Income Fund
PIMCO High Income Fund is a closed-end management investment company. The company's primary investment objective is to seek high current income. Its secondary objective is to seek capital appreciation.
About DNA Ginkgo Bioworks Holdings Inc.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.